@failedLyndonLaRouchite @merz @jgordon @DeanBaker13 yes. but those big pharma partners largely serve as VCs plus compliance / clinical trial specialists. those can be challenging competencies, but they can also be reorganized! i’m not saying things aren’t “hard”. but when (inherently hard) trials are run by financial beneficiaries they are at risk of being corrupt. that things are difficult doesn’t mean the way we currently do them is best.